{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"high-risk prostate cancer","name":"SRAM","nct_id":"NCT03938649","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sram-nct03938649. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).\n* 38 fractions of daily treatment, Monday to Friday","label":"Conventional IMRT","type":"EXPERIMENTAL"},{"description":"* RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)\n* 5 fractions of weekly treatment. Once fraction per week.","label":"SBRT","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Advanced Prostate Cancer"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Conventional IMRT","otherNames":[],"type":"RADIATION"},{"name":"SBRT","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-04","lead_sponsor":"CCTU","official_title":"Randomized Phase II Study of Combination Androgen Deprivation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer: Stereotactic Body Radiotherapy vs conventionAl IMRT to Prostate and Pelvic Nodes (SRAM Study)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To compare acute toxicities between SBRT and conventional IMRT","timeFrame":"4 years"}],"references":[],"start_date":{"date":"2019-05-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SRAM study_Postate Cancer","url":"https://clinicaltrials.gov/study/NCT03938649"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sram-nct03938649"}